Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice

Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice

A therapeutic vaccine for human Chagas disease (American trypanosomiasis caused by Trypanosoma cruzi) is under development based on the success of vaccinating mice with DNA constructs expressing the antigens Tc24 and Tc-TSA-1. However, because DNA and nucleic acid vaccines produce less than optimal...

Full description

Bibliographic Details
Main Authors: Juan Jose de la Cruz, Liliana Villanueva-Lizama, Victor Dzul-Huchim, María-Jesus Ramírez-Sierra, Pedro Martinez-Vega, Miguel Rosado-Vallado, Jaime Ortega-Lopez, Claudia Ivonne Flores-Pucheta, Portia Gillespie, Bin Zhan, Maria Elena Bottazzi, Peter J. Hotez, Eric Dumonteil
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
chagas disease
vaccine
recombinant protein
parasite
production
Online Access:http://dx.doi.org/10.1080/21645515.2018.1520581

Internet

http://dx.doi.org/10.1080/21645515.2018.1520581

Similar Items